Daiichi Sankyo Pharmaceutical has launched silodosin for the treatment of dysuria associated with benign prostatic hyperplasia in China.
Silodosin works by inhibiting the alpha 1A-adrenergic receptor and relieving tension in the prostate, lessening pressure and reducing urethral resistance.
Kissei Pharmaceutical discovered silodosin, a selective alpha 1A-adrenoceptor antagonist existing mainly in the prostate.
Daiichi Sankyo and Kissei Pharmaceutical have been jointly marketing silodosin under the brand name, Urief, in Japan since May 2006.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/daiichi-sankyo-launches-dysuria-therapy-in-china-220413